A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2 negative gastroesophageal adenocarcinomas

Background Gastroesophageal adenocarcinoma (GEA) is a major cause of global cancer-related deaths. A first-line standard of care for advanced GEA is FOLFOX, with the addition of immune checkpoint inhibitors (ICIs) in patients with a programmed death-ligand 1 (PD-L1) combined positive score of ≥1. However, overall survival remains poor. There is a strong mechanistic rationale for cooperativity between anti-vascular endothelial growth factor (VEGF) antibodies and ICIs across cancers. Ivonescimab is a bispecific antibody that simultaneously targets programmed cell death protein 1 and VEGF, with evidence of safety and efficacy in colorectal, hepatocellular, and lung cancers. Design This single-arm, multi-institutional, phase II study seeks to evaluate ivonescimab in combination with FOLFOX as a first-line therapy in GEA. Adults with locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative GEA are eligible. Positive PD-L1 expression is not required for eligibility. We plan to enroll 40 patients. Ivonescimab 20 mg/kg and FOLFOX are given on day 1 and day 15 of a 28-day cycle. Treatment will continue until disease progression, withdrawal of consent, or death. The primary objective is to define the efficacy of ivonescimab in combination with FOLFOX as measured by the 6-month progression-free survival rate. Translational correlative studies are planned to explore tumor and immunologic determinants of response.

Authors

Institutions

Publication Details

Journal
ESMO Gastrointestinal Oncology
Published
2026-11-12
DOI
https://doi.org/10.1016/j.esmogo.2026.100442
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2 negative gastroesophageal adenocarcinomas

Z.A. Wainberg, Haley Barnes, Lindor Qunaj, İlyas Şahin et al.
ESMO Gastrointestinal Oncology
Cancer Immunotherapy and Biomarkers
article

A single-arm, phase II study of ivonescimab in combination with FOLFOX in advanced HER2 negative gastroesophageal adenocarcinomas

Z.A. Wainberg, Haley Barnes, Lindor Qunaj, İlyas Şahin, Haeseong Park, Samuel Jacob Klempner, Sienna Durbin, Sean T. Bannon, M.R. Strickland, C. Simms, D.T. Ting, R.B. Corcoran, H. Zheng
article en

Abstract

Background Gastroesophageal adenocarcinoma (GEA) is a major cause of global cancer-related deaths. A first-line standard of care for advanced GEA is FOLFOX, with the addition of immune checkpoint inhibitors (ICIs) in patients with a programmed death-ligand 1 (PD-L1) combined positive score of ≥1. However, overall survival remains poor. There is a strong mechanistic rationale for cooperativity between anti-vascular endothelial growth factor (VEGF) antibodies and ICIs across cancers. Ivonescimab is a bispecific antibody that simultaneously targets programmed cell death protein 1 and VEGF, with evidence of safety and efficacy in colorectal, hepatocellular, and lung cancers. Design This single-arm, multi-institutional, phase II study seeks to evaluate ivonescimab in combination with FOLFOX as a first-line therapy in GEA. Adults with locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative GEA are eligible. Positive PD-L1 expression is not required for eligibility. We plan to enroll 40 patients. Ivonescimab 20 mg/kg and FOLFOX are given on day 1 and day 15 of a 28-day cycle. Treatment will continue until disease progression, withdrawal of consent, or death. The primary objective is to define the efficacy of ivonescimab in combination with FOLFOX as measured by the 6-month progression-free survival rate. Translational correlative studies are planned to explore tumor and immunologic determinants of response.

ESMO Gastrointestinal OncologyVol. 14
University of California, Los Angeles (US), Massachusetts General Hospital (US), UCLA Jonsson Comprehensive Cancer Center (US)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon